Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Generic Unithroid approval

Executive Summary

FDA approves Mylan ANDA for Jerome Stevens' Unithroid (levothyroxine) on June 5. Jerome Stevens is seeking $1.3 bil. from FDA for allegedly posting trade secrets from its NDA, approved in August 2000, on the agency website (1"The Pink Sheet" April 1, In Brief)...

You may also be interested in...

Levothyroxine Review Standards Should Be Same For ANDAs, Brands – Petition

Levothyroxine generics should be held to the same review standards as their 505(b)(2) counterparts, Unithroid manufacturer Jerome Stevens maintained in a 1citizen petition to FDA

User fee increase coming?

Jerome Stevens Pharmaceuticals is seeking $1.3 bil. from FDA for the agency's "unlawful publication of trade secrets and confidences" for Unithroid on its web site, the company announces March 26. The claim approaches the agency's $1.7 bil. annual operating budget. FDA posted trade secrets from its October 1999 levothyroxine NDA from Aug. 22, 2000 to Jan. 23, 2001, the company said. JSP will sue the agency in D.C. federal court if FDA fails to act on the tort claim within six months...

Amgen/AstraZeneca’s Tezepelumab Cuts Asthma Exacerbations By 56%

Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics. 




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts